Insiders recently spent $5-million picking up shares in INK Canadian Insider Index member Bausch Health Companies Inc., formerly Valeant Pharmaceuticals International Inc.
The public-market purchases followed a pair of mid-month announcements.
On Sept. 11, Bausch reported it had reduced debt by $107-million. The next morning, it reported an agreement that resolved intellectual property litigation regarding XIFAXAN tablets.
Earlier in August, Bausch upped guidance for 2018 adjusted EBITDA.
One of the insiders buying was chairman and chief executive Joseph Papa, who acquired 30,000 shares.
Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.
Chart reflects public-market transactions of common shares or unit trusts by company officers and directors.
Ted Dixon